“…We have developed a series of thieno[2,3-d]-pyrimidine derivatives with the properties of allosteric agonists and (or) ago-PAMs and allosteric antagonists of LHR [ 324 , 325 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 ]. Compounds TP03 and TP04, the most active of the full agonists, stimulated the AC activity in testicular membranes isolated from the rat testes, increased testosterone production by the cultured Leydig cells, and also stimulated testicular steroidogenesis and increased testosterone levels when administered intraperitoneally, subcutaneously, and orally to both healthy male rats and animals with androgen deficiency caused by types 1 and 2 diabetes mellitus and aging [ 395 , 400 , 402 , 403 , 404 ]. Using molecular docking, it was found that the efficiency and selectivity of the studied thieno[2,3-d]-pyrimidines correlate with the characteristics of their binding to the transmembrane allosteric site of LHR, and the key parameter of such binding was the intensity of hydrophobic contact while the Coulomb interactions and hydrogen bonds were less significant [ 400 ].…”